[PRNewswire] Handheld Technology from Baxter Makes Diabetic Retinopathy
Screening Simple and Affordable for Primary Care Settings
-- Early Detection Can Prevent 95% of Vision Loss Cases
(SEOUL, South Korea, July 25, 2022 PRNewswire=연합뉴스) Diabetic retinopathy is the leading cause of blindness among working-age adults globally.[1] With early detection and treatment, as much as 95 percent of vision loss cases can be prevented.[2] Compliance with annual diabetic retinal exams in South Korea was found to be approximately 53%, with only 73% of those taking place in the last 12 months.[3] Up to 80% of individuals with type two diabetes may eventually develop some stage of diabetic retinopathy.[4]
The Welch Allyn(R) RetinaVue™ 100 Imager PRO enables diabetic retinopathy screening in primary care settings. By quickly and comfortably screening patients as part of their routine primary care visit, it has been shown that RetinaVue can double patient compliance for potentially vision-saving annual diabetic retinal exams (DREs) in 12 months.[5]
"Diabetes is an epidemic. Diabetic retinopathy is the leading cause of vision loss among adults 20-to-74 years of age,[6] affecting 7.7 million people worldwide.[7] It is simply tragic that a large percentage of patients with diabetes aren't being screened for diabetic retinopathy, when it's one of the most preventable causes of blindness among adults," said Bruce Peatey, Vice President of Baxter, Asia Pacific. "RetinaVue has the potential to change lives by helping to identify diabetic retinopathy in those individuals who had not previously been screened for the disease, enhancing the potential to save the sight of thousands, if not millions, of people with diabetes."
Baxter makes this possible by reducing the cost barrier for high-quality fundus imaging. The RetinaVue 100 Imager PRO costs significantly less than full-size fundus cameras, yet the imager is designed such that any healthcare professional in a primary care practice can capture high-quality fundus images with minimal training.
With nonmydriatic capture through a 3.0mm pupil, the RetinaVue 100 Imager PRO enables comfortable exams without pharmacologic dilation. The handheld, portable device is an attractive solution for mobility across multiple locations. The solution utilizes proprietary touchless auto-focus/image-capture technology and integrated image-quality assessment algorithms, which can help reduce your need for re-imaging appointments. You will get an immediate quality score on the image you capture.
The device will be available in South Korea beginning July 25, 2022. Through RetinaVue, Baxter is committed to delivering simple and affordable screening solutions to help save vision for patients living with diabetes in primary care. For more information, please visit www.baxter.com or https://www.hillrom.kr/ko/solutions/combating-chronic-disease-apac/Diabetic-Retinopathy/
[1]. Diabetic Retinopathy | Fred Hollows Foundation
[2]. Facts About Diabetic Eye Disease; The National Eye Institute (NEI); https://nei.nih.gov/health/diabetic/retinopathy
[3]. https://drbarometer.com/docs/default-source/dr-barometer-study-finding-documents/countries/south-korea/dr-barometer-south-korea-report.pdf?sfvrsn=e1f0cfdf_2 PAGE 134.
[4]. Lee DJ, Kumar N, Feuer WJ, et al. BMJ Open Diabetes Res Care. 2014;2(1):e000031.
[5]. Telemedicine and Retinal Imaging for Improving Diabetic Retinopathy Evaluation; Archives of Internal Medicine; Vol.172, Num. 21, 2012
[6]. Updated: Centers for Disease Control and Prevention. Vision Health Initiative (VHI). https://www.cdc.gov/visionhealth/basics/ced/ Published September 29, 2015. Updated September 29, 2015. Accessed January 30, 2020.
[7]. National Eye Institute. Diabetic Retinopathy Data and Statistics. https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/diabetic-retinopathy-data-and-statistics Published July 17, 2019. Updated July 17, 2019. Accessed February 24, 2020.
About Baxter
Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter [https://twitter.com/baxter_intl ], LinkedIn [https://www.linkedin.com/company/baxter-healthcare/ ] and Facebook [https://www.facebook.com/BaxterInternational ].
CONTACT INFORMATION
Investor Relations
Contact: Clare Trachtman, Vice President, Investor Relations
Phone: 312-819-9387
Email: sullivc@baxter.com
Media
Contact: Bella Ling, Senior Director of Communications, APAC & Greater China
Phone: +86 136 4196 2389
Email: Bella.ling@baxter.com
Logo - https://mma.prnewswire.com/media/1860802/Baxter_PNG_Logo_Logo.jpg
Source: Baxter
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Screening Simple and Affordable for Primary Care Settings
-- Early Detection Can Prevent 95% of Vision Loss Cases
(SEOUL, South Korea, July 25, 2022 PRNewswire=연합뉴스) Diabetic retinopathy is the leading cause of blindness among working-age adults globally.[1] With early detection and treatment, as much as 95 percent of vision loss cases can be prevented.[2] Compliance with annual diabetic retinal exams in South Korea was found to be approximately 53%, with only 73% of those taking place in the last 12 months.[3] Up to 80% of individuals with type two diabetes may eventually develop some stage of diabetic retinopathy.[4]
The Welch Allyn(R) RetinaVue™ 100 Imager PRO enables diabetic retinopathy screening in primary care settings. By quickly and comfortably screening patients as part of their routine primary care visit, it has been shown that RetinaVue can double patient compliance for potentially vision-saving annual diabetic retinal exams (DREs) in 12 months.[5]
"Diabetes is an epidemic. Diabetic retinopathy is the leading cause of vision loss among adults 20-to-74 years of age,[6] affecting 7.7 million people worldwide.[7] It is simply tragic that a large percentage of patients with diabetes aren't being screened for diabetic retinopathy, when it's one of the most preventable causes of blindness among adults," said Bruce Peatey, Vice President of Baxter, Asia Pacific. "RetinaVue has the potential to change lives by helping to identify diabetic retinopathy in those individuals who had not previously been screened for the disease, enhancing the potential to save the sight of thousands, if not millions, of people with diabetes."
Baxter makes this possible by reducing the cost barrier for high-quality fundus imaging. The RetinaVue 100 Imager PRO costs significantly less than full-size fundus cameras, yet the imager is designed such that any healthcare professional in a primary care practice can capture high-quality fundus images with minimal training.
With nonmydriatic capture through a 3.0mm pupil, the RetinaVue 100 Imager PRO enables comfortable exams without pharmacologic dilation. The handheld, portable device is an attractive solution for mobility across multiple locations. The solution utilizes proprietary touchless auto-focus/image-capture technology and integrated image-quality assessment algorithms, which can help reduce your need for re-imaging appointments. You will get an immediate quality score on the image you capture.
The device will be available in South Korea beginning July 25, 2022. Through RetinaVue, Baxter is committed to delivering simple and affordable screening solutions to help save vision for patients living with diabetes in primary care. For more information, please visit www.baxter.com or https://www.hillrom.kr/ko/solutions/combating-chronic-disease-apac/Diabetic-Retinopathy/
[1]. Diabetic Retinopathy | Fred Hollows Foundation
[2]. Facts About Diabetic Eye Disease; The National Eye Institute (NEI); https://nei.nih.gov/health/diabetic/retinopathy
[3]. https://drbarometer.com/docs/default-source/dr-barometer-study-finding-documents/countries/south-korea/dr-barometer-south-korea-report.pdf?sfvrsn=e1f0cfdf_2 PAGE 134.
[4]. Lee DJ, Kumar N, Feuer WJ, et al. BMJ Open Diabetes Res Care. 2014;2(1):e000031.
[5]. Telemedicine and Retinal Imaging for Improving Diabetic Retinopathy Evaluation; Archives of Internal Medicine; Vol.172, Num. 21, 2012
[6]. Updated: Centers for Disease Control and Prevention. Vision Health Initiative (VHI). https://www.cdc.gov/visionhealth/basics/ced/ Published September 29, 2015. Updated September 29, 2015. Accessed January 30, 2020.
[7]. National Eye Institute. Diabetic Retinopathy Data and Statistics. https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/diabetic-retinopathy-data-and-statistics Published July 17, 2019. Updated July 17, 2019. Accessed February 24, 2020.
About Baxter
Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter [https://twitter.com/baxter_intl ], LinkedIn [https://www.linkedin.com/company/baxter-healthcare/ ] and Facebook [https://www.facebook.com/BaxterInternational ].
CONTACT INFORMATION
Investor Relations
Contact: Clare Trachtman, Vice President, Investor Relations
Phone: 312-819-9387
Email: sullivc@baxter.com
Media
Contact: Bella Ling, Senior Director of Communications, APAC & Greater China
Phone: +86 136 4196 2389
Email: Bella.ling@baxter.com
Logo - https://mma.prnewswire.com/media/1860802/Baxter_PNG_Logo_Logo.jpg
Source: Baxter
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
